Detalhe da pesquisa
1.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood
; 137(8): 1019-1023, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167024
2.
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Lancet Haematol
; 6(9): e470-e479, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31324600